Medicine and Dentistry
Infection
100%
Therapeutic Procedure
57%
Antibiotics
37%
Clinical Trial
26%
Antiinfective Agent
19%
Metronidazole
18%
Infectious Disease Treatment
15%
Diseases
14%
Microbiome
13%
Spore
13%
Kidney Injury
11%
Systematic Review
11%
Immunocompromised Patient
11%
Gastrointestinal Infection
11%
Antimicrobial Therapy
11%
Toxoid
11%
Broad-Spectrum Antibiotic
11%
Tazobactam
11%
Retrospective Study
11%
Ambulatory Care
11%
Recurrent Disease
11%
Ceftolozane
11%
Next Generation Sequencing
11%
Fulminant
11%
Antibiogram
11%
Carbapenem
11%
Vaborbactam
11%
Relebactam
11%
Gut Microbiota
11%
Ridinilazole
10%
Vancomycin
10%
Dysbiosis
7%
Clindamycin
5%
Quinolone Derivative
5%
Erythromycin
5%
Health Outcomes
5%
Cohort Effect
5%
Ribotyping
5%
Clinician
5%
Cephalosporin
5%
Group Sex
5%
In Vitro
5%
Odds Ratio
5%
Fecal Microbiota Transplantation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
79%
Ridinilazole
15%
Recurrent Disease
14%
Vancomycin
13%
Antibiotic Agent
12%
Pharmacotherapy
11%
Drug Discovery
11%
Carbapenem
11%
Antibiotic Therapy
11%
Kidney Injury
11%
Gastrointestinal Infection
11%
Tazobactam
11%
Ceftolozane
11%
Genetic Susceptibility
11%
Toxoid
11%
Gram Negative Infection
11%
Meropenem
11%
Vaborbactam
11%
Intracellular Bacterium
11%
Antibiotics
9%
Feces microflora
8%
Antiinfective Agent
5%
Dysbiosis
5%
Cephalosporin Derivative
5%
Quinolone Derivative
5%
Erythromycin
5%
Clindamycin
5%
Fidaxomicin
5%
Infectious Agent
5%
Microflora
5%
Clinical Trial
5%
Metronidazole
5%
Immunology and Microbiology
Meropenem/Vaborbactam
22%
Pseudomonas aeruginosa
22%
MIC50
18%
Infectious Disease
18%
Broth Dilution
15%
Enterobacterales
11%
Eosinophil Count
11%
Intestine Flora
11%
Feces microflora
11%
Creatinine Blood Level
11%
Vaccine Efficacy
11%
Minimum Inhibitory Concentration
11%
Antibiotic Sensitivity
11%
Toxoid
7%
Bezlotoxumab
5%
Bacterial Strain
5%
Hospital Mortality
5%
MIC90
5%
Population Dynamics
5%
